LONDON, UK: PureTech Health plc , a clinical-stage biotherapeutics company announces that its Founded Entity, Vedanta Biosciences completed a $68 million Series D financing. Vedanta plans to use the proceeds to advance its pipeline of defined bacterial consortia, including progressing VE303 into a Phase 3 clinical trial in patients at high risk for recurrent CDI, initiating…